ANZCTR search results

Most hospitals re-site peripheral intravenous catheters in adults every 72-96 hours, based on current Centers of Disease Control and Prevention Guidelines. This is at odds with regimes for children, and critically ill patients, where cannulas are only re-sited when clinically indicated. Recent prospective surveillance studies have demonstrated the safety of longer dwell times but these observations have not been validated in adults, using randomised controlled trial methodology. The primary aim of the present study is to compare the rates of peripheral catheter-related local infection, phlebitis and obstruction between two groups of patients - those having routine catheter changes every 72 hours and those having catheter changes only when clinically indicated.

The study has been published A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study. Isbister GK, Brown SG, Miller M, Tankel A, Macdonald E, Stokes B, Ellis R, Nagree Y, Wilkes GJ, James R, Short A, Holdgate A. QJM. 2008 Jul;101(7):557-65.

This study is designed to evaluate the therapeutic application of repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for depression.

Poor vision is a risk factor for falls among older people but it is not known whether improving vision prevents falls. In this study, subjects in the intervention group have a comprehensive eye examination and receive appropriate treatment. It is hoped that this will result in fewer falls over the next 12 months than in an untreated control group.

To assess the efficacy and safety of delayed onset Certican (Everolimus) compared to Myfortic (enteric coated Mycophenolate Sodium: MPS), both arms in combination with Cyclosporin A (CsA)(monitored by C2 levels) and corticosteroids for the prevention of chronic rejection (Bronchiolitis Obliterans Syndrome: BOS) in the first 3 years post transplant when given as de novo maintenance therapy for the management of lung allograft recipients after bronchial anastomotic healing has been confirmed at bronchoscopy.

This is a randomised, open label, multicentre clinical trial of two different doses of imatinib to test whether there is any difference in disease outcome between the doses in patients with unresectable or metastatic malignant gastrointestinal stromal tumours (GIST). Recruitment opened in 2001, closed in 2002 with 946 patients worldwide and 116 at Australian, NZ and Singapore sites. Long term Follow UP closed October 2016.

This randomised controlled trial compares the new diagnostic strategy for Invasive Aspergillosis (IA) to the current standard diagnostic strategy. The new diagnostic strategy uses Aspergillus ELISA and an Aspergillus nested PCR assay to diagnose/exclude IA and direct further management including timing of HRCT scan of thorax. Eligible patients are aged 18-80 and have received an allogeneic haematopoietic stem cell transplant or are undergoing intensive combination chemotherapy for acute myeloid leukaemia or acute lymphoblastic leukaemia. The study aims to determine which strategy results in lower: rates of empiric antifungal therapy administration; drug–related toxicities; IA-related mortality rates and overall mortality rates.